Skip to main content

and
  1. Article

    Open Access

    Patient-Reported Outcomes with Insulin Glargine 300 U/mL in People with Type 2 Diabetes: The MAGE Multicenter Observational Study

    MAGE was a Multicenter, single-Arm, observational 6-month (plus 6-month extension) study that aimed to assess treatment satisfaction, efficacy, and safety of insulin Glargine 300 U/mL (Gla-300) in people with ...

    Ides M. Colin, Kathy Alexandre, Jacques Bruhwyler, André Scheen in Diabetes Therapy (2020)

  2. Article

    Open Access

    Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study

    OPTIMIZE evaluated the efficacy, safety and treatment satisfaction of insulin glargine 300 U/mL once daily (Gla-300 OD) in people with type 1 diabetes mellitus (T1DM) previously uncontrolled on basal insulin t...

    Chantal Mathieu, S. John Weisnagel, Peter Stella, Jacques Bruhwyler in Diabetes Therapy (2020)